# Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients

> **NCT01779401** · NA · COMPLETED · sponsor: **Chinese Academy of Medical Sciences, Fuwai Hospital** · enrollment: 1078 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** Clopidogrel 75mg
- **DRUG:** Clopidogrel 150mg
- **DRUG:** Aspirin 100mg
- **DRUG:** Cilostazol 100mg

## Key facts

- **NCT ID:** NCT01779401
- **Lead sponsor:** Chinese Academy of Medical Sciences, Fuwai Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 1078 (ACTUAL)
- **Last updated:** 2017-07-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01779401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01779401, "Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01779401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*